KalVista Pharmaceuticals
KALV
KALV
48 hedge funds and large institutions have $278M invested in KalVista Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
48
Holders Change
+22
Holders Change %
+84.62%
% of All Funds
1.1%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.09%
New
25
Increased
9
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$23.4M |
| 2 |
VMI
VHCP Management II
New York
|
+$16.8M |
| 3 |
DM
Deerfield Management
New York
|
+$14.4M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$13.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.75M |
Top Sellers
| 1 |
TI
Telemetry Investments
New York
|
-$865K |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$545K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$379K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
-$167K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$52.1K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
51
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -231 | Closed |
|